Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-BCMA CAR-T in Relapsed or Refractory Multiple Myeloma
NCT05577000Phase 1Active, not recruiting
- Start
- Oct 2021
- Primary completion
- Nov 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of anti-BCMA CAR-T cells in multiple myeloma (MM) (4 arms). Primary endpoints: Proportion of participants with treatment-emergent adverse events at 29 days, Proportion of participants who experience a dose-limiting toxicity at 29 days and 1 more. Started Oct 2021; status: active, not recruiting.
02
Drugs
anti-BCMA CAR-T cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05577000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05577000.